Trifluoperazine (sold as Eskazinyl®, Eskazine®, Jatroneural®, Modalina®, Stelazine®, Terfluzine®) is a typical antipsychotic drug of the phenothiazine group. Trifluoperazine is a highly potent drug (approx. 20-times more potent than Chlorpromazine).
Pharmakokinetics
Little is known about human pharmacokinetics. One study has the following results:
A study of the pharmacokinetics of trifluoperazine as a single 5-mg dose by mouth in 5 healthy subjects. Peak plasma concentrations of trifluoperazine were reached from 1.5 to 4.5 hours after ingestion and varied widely between subjects, ranging from 0.53 to 3.09 ng per mL. Elimination of trifluoperazine was multiphasic; the mean elimination half-life was estimated to be 5.1 hours over the period from 4.5 to 12 hours after ingestion, while the mean apparent terminal elimination half-life was estimated to be 12.5 hours.
Uses
The primarary indication of trifluoperazine is
schizophrenia. Its use in many parts of the world has declined because of highly frequent and severe early and late (
tardive dyskinesia)
extrapyramidal symptoms.
The annual development rate of tardive dyskinesia may be as high as 4%.
More on
[ Trifluoperazine ]
Trifluoperazine - Familydoctor.org - Information for patients in English and Spanish.